August 21, 2019 NIAID Funding News
Read this full issue online at http://www.niaid.nih.gov/
It’s now been a decade since criterion scores were introduced in the peer review process, and yet there is still some confusion about how these scores are used.
Opportunities and Resources
NIH’s Commercialization Accelerator Program helps small business grantees establish market and customer relevance, build commercial relationships, and focus on revenue opportunities.
You should target specific due dates to minimize the hiatus between the end of your existing award and the start of your potential renewal award.
In The News
If you submit clinical trial research to a funding opportunity announcement that does not allow clinical trial research, or vice versa, NIH may withdraw the application without review.
If your progress toward an independent research career is interrupted by medical concerns, disability, family care responsibilities, extended periods of clinical training, natural disasters, or active duty military service, NIH may extend your early-stage investigator status beyond 10 years.
Researchers, explore NIH’s free public data to discover emerging research trends, potential collaborators or competitors, publications, patents, and NIH program officers.
New Funding Opportunities
- PAR-19-351, Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K08/K23 Recipients (R21, Clinical Trial Not Allowed)
- PAR-19-346, Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R21, Clinical Trial Not Allowed)
- PAR-19-347, Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R03, Clinical Trial Not Allowed)
- RFA-HL-20-030, Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3, Clinical Trial Required)
See other announcements at Opportunities & Announcements.
Send suggestions or comments to email@example.com.